ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02312115` - Delayed Renal Allograft Function and Furosemide Treatment	Phase 2
Completed	`NCT02134314` - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI	Phase 1/Phase 2
Completed	`NCT02346968` - Evaluation of CAF22 After Renal Transplantation
Completed	`NCT01794663` - Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function	Phase 2
Completed	`NCT00298181` - YSPSL for Prevention of Delayed Graft Function Part A	Phase 1/Phase 2
Not yet recruiting	`NCT05166460` - Novel Cooling Device for the Elimination of Warm Ischemia During Renal Transplantation	N/A
Recruiting	`NCT03071536` - Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation	N/A
Not yet recruiting	`NCT05513807` - Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant	Phase 3
Recruiting	`NCT04005469` - Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation	Phase 1/Phase 2
Completed	`NCT01848249` - Deceased Donor Biomarkers and Recipient Outcomes
Active, not recruiting	`NCT02474667` - Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney	Phase 3
No longer available	`NCT02026934` - CliniMACS® CD34+ Reagent System for Expanded Access Use	N/A
Terminated	`NCT00217152` - A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors	Phase 4
Recruiting	`NCT05430620` - Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys	Phase 3
Completed	`NCT03864926` - Envarsus in Delayed Graft Function (E-DGF)	Phase 4
Recruiting	`NCT06367205` - Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations	N/A
Completed	`NCT02610296` - QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant	Phase 3
Active, not recruiting	`NCT02568696` - Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function
Recruiting	`NCT01837043` - Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function	Phase 2
Terminated	`NCT01878786` - A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys	Phase 2/Phase 3

NCT number	NCT05907096
Study type	Interventional
Source	argenx
Contact	Sabine Coppieters, MD
Phone	857-350-4834
Email	Clinicaltrials@argenx.com
Status	Recruiting
Phase	Phase 2
Start date	February 17, 2024
Completion date	December 2026

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function — VARVARA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms